Sarepta Therapeutics Inc. (SRPT)

153.10
5.51 3.73
NASDAQ : Health Technology
Prev Close 147.59
Open 150.29
Day Low/High 148.07 / 153.50
52 Wk Low/High 42.97 / 176.50
Volume 1.06M
Avg Volume 1.14M
Exchange NASDAQ
Shares Outstanding 66.44M
Market Cap 10.15B
EPS -0.90
Div & Yield N.A. (N.A)

Latest News

There Is No Rush to Buy Micron

There Is No Rush to Buy Micron

It's not different this time, semiconductors are still cyclical.

Six Biotechnology Names on My Watch List

Six Biotechnology Names on My Watch List

After recent weakness in the biotech sector, here are some names to start watching.

Parent Project Muscular Dystrophy And Sarepta Therapeutics Partner To Launch Duchenne Outcomes Research Interchange, A Patient-Data Warehouse Serving The Entire Duchenne Community

Parent Project Muscular Dystrophy And Sarepta Therapeutics Partner To Launch Duchenne Outcomes Research Interchange, A Patient-Data Warehouse Serving The Entire Duchenne Community

Building on PPMD's 10-Year-Old Duchenne Registry, the largest Patient Reported Outcomes Registry for the Disease, and Sarepta Therapeutics' Leadership with the First U.S.-Approved Therapy, New Interchange is Scheduled for 2019 Launch

The Market Is Finally Pulling Back

The Market Is Finally Pulling Back

This is a healthy pullback in a market that was a little overheated.

Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz

Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz

Despite $5.1 billion deal for Costa, I'm not slurping any KO up.

A Lesson to Learn From Thursday's Market Action

A Lesson to Learn From Thursday's Market Action

You don't have to be Sigmund Freud to understand the psychology here.

HPE: Surpassing Expectations, Raising Guidance Incrementally

HPE: Surpassing Expectations, Raising Guidance Incrementally

If estimates continue to come up there will be institutional interest in the stock.

3 Stock Trades I'm Looking to Make on the U.S.-Mexico Trade Deal

3 Stock Trades I'm Looking to Make on the U.S.-Mexico Trade Deal

There are several key points to keep in mind as you digest this news.

Fear of Missing Out Outweighs Fear of Trump Political Fallout

Fear of Missing Out Outweighs Fear of Trump Political Fallout

If the market wanted an excuse to sell off it had it.

Sony, United Rentals, Marathon Petroleum: 'Mad Money' Lightning Round

Sony, United Rentals, Marathon Petroleum: 'Mad Money' Lightning Round

Jim Cramer weighs in on Sony, United Rentals, Marathon Petroleum, Royal Dutch Shell, Lam Research, NuStar Energy, Ebix and more.

Walmart Fuels Monster Move: Cramer's 'Mad Money' Recap (Thursday 8/16/18)

Walmart Fuels Monster Move: Cramer's 'Mad Money' Recap (Thursday 8/16/18)

Walmart -- with great growth -- sparks optimism, but Jim Cramer says it's not the only stock to fuel the day's rally.

Don't Chase Walmart Here

Don't Chase Walmart Here

After rallying to more than $100 a share, the stock could pull back to around $95 before consolidating gains.

Prepare For the Worst but Stay Positive

Prepare For the Worst but Stay Positive

The market has wanted to sell-off for a while and finally it is doing it.

Little Fear of Missing Out as Stocks Hold Gains

Little Fear of Missing Out as Stocks Hold Gains

While markets are higher Tuesday, there is little to suggest recent choppy action won't continue.

Fears Over Turkey Ease, but Don't Expect a Strong Market Uptrend

Fears Over Turkey Ease, but Don't Expect a Strong Market Uptrend

The bounce this morning is producing a sigh of relief, but this is going to remain a difficult trading market.

Overly Aggressive Dip Buyers Finally Trapped

Overly Aggressive Dip Buyers Finally Trapped

For a long time now one of the most consistent patterns in the market has been buying dips created by negative headlines.

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Apple in particular is helping the bullish cause.

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Sarepta Therapeutics, Inc. And CureDuchenne To Host Webinar On Duchenne Muscular Dystrophy Programs Utilizing Sarepta's RNA-Targeted Technology Platforms

Sarepta Therapeutics, Inc. And CureDuchenne To Host Webinar On Duchenne Muscular Dystrophy Programs Utilizing Sarepta's RNA-Targeted Technology Platforms

Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and non-profit CureDuchenne announced today they have...

Biogen: Let the Situation Cool Off a Bit Before Buying

Biogen: Let the Situation Cool Off a Bit Before Buying

There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.

Unexciting Holiday Trading

Unexciting Holiday Trading

That shouldn't stop us from looking for some good short term trades.

Bounce Opportunities Are the Name of the Game

Bounce Opportunities Are the Name of the Game

Everyone is a buyer of pullbacks when the market is going up but not so much when it's going down.

FAANG Stocks Are Being Nailed

FAANG Stocks Are Being Nailed

There are likely to be some good opportunities developing as this profit taking accelerates.

Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back

Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back

Sarepta adds another 7% on top of nearly 40% gains on Tuesday following good results for a new gene therapy.

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Sentiment is very positive, regardless of what the indices may say.

Biotech Sector Steps Up to Provide Some Strong Action for Traders

Biotech Sector Steps Up to Provide Some Strong Action for Traders

The S&P 500 has shown the same pattern for three consecutive days.

Biotech Firm Sarepta Surges 40% on Positive Test Results

Biotech Firm Sarepta Surges 40% on Positive Test Results

But rival firm PTC Therapeutics tumbles nearly 31% on the news.

A Weak Close Is Going to Have a Significant Impact on Sentiment

A Weak Close Is Going to Have a Significant Impact on Sentiment

It is important for the bulls that the indices close near the highs of the day.

TheStreet Quant Rating: D (Sell)